Belay Diagnostics Reports 82% Clinical Impact Rate for Summit™ and Vantage™ in CNS Lymphoma Study
PR Newswire —
CHICAGO, March 24, 2026 /PRNewswire/ -- Belay Diagnostics announced the publication of a new retrospective study demonstrating that its Summit and Vantage tests provided meaningful clinical impact in 82% of CNS lymphoma cases evaluated. The study, which analyzed 50 specimens from 48...